NASDAQ:MDVXU

Medovex (MDVXU) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
880,077 shs
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

About Medovex

Medovex Corp. is a development-stage company. The Company focuses on obtaining, developing and commercializing various intellectual property rights (patents, patent applications and knowhow) in the medical technology area, with particular focus on the development of medical devices. It focuses on development and commercialization of the DenerveX System, which consists of the DenerveX Device and the DenerveX Pro-40 power generator (DenerveX). DenerveX is a device that is intended to be used in the treatment of conditions resulting from the degeneration of joints in the spine that cause back pain. The DenerveX Pro-40 Power Generator is the power source for the DenerveX System. The system works in synchronization to deliver controlled and precise therapy to patients with facet joint pain. DenerveX combines two procedures in one: capsular tissue removal through a light tissue scraping action and radio ablation denervation. DenerveX is commercially not available in the United States.

MDVXU Stock News Headlines

A new way to collect income from stocks
Most people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively…
Imprimerie Chirat SA (CHRA)
Sella Real Estate (SLARL)
Visionaryholdings Co Ltd (9263)
See More Headlines
Receive MDVXU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Medovex and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
N/A
Industry
N/A
Sub-Industry
N/A
Current Symbol
NASDAQ:MDVXU
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Jesse Crowne (Age 33)
    Executive Co-Chairman of the Board
  • Larry W. Papasan (Age 77)
    Co-Chairman of the Board
  • Patrick Kullmann (Age 61)
    President
  • Jarrett Gorlin (Age 40)
    Chief Executive Officer, Director
  • Charles Duane Farrahar (Age 56)
    Chief Financial Officer, Company Secretary
  • Dennis Moon (Age 41)
    Senior Vice President
  • James R. Andrews M.D. (Age 74)
    Director
  • Randal R. Betz M.D. (Age 59)
    Director
  • Ron Lawson (Age 72)
    Director
  • Jon Mogford Ph.D. (Age 49)
    Director

MDVXU Stock Analysis - Frequently Asked Questions

When did Medovex IPO?

Medovex (MDVXU) raised $8 million in an initial public offering (IPO) on Friday, December 19th 2014. The company issued 1,400,000 shares at a price of $5.75 per share. Laidlaw & Company (UK) Ltd. served as the underwriter for the IPO.

This page (NASDAQ:MDVXU) was last updated on 4/25/2024 by MarketBeat.com Staff

From Our Partners